Next Generation vaccines

Abera is developing the next generation vaccines and immunotherapies based on our proprietary vaccine delivery platform.

hexa-02 copy
Laboratory blue

Technology

With the novel vaccine platform BERA, Abera can decorate Outer Membrane Vesicles (OMVs) with large amounts of antigen of one or more varieties. The OMVs enhances the immune response and antigen provides strong and broad protection.

cdc-ruFBkCruBVk-unsplash-

Vaccine targets

Abera develops a pipeline of vaccine candidates based on its proprietary technology. The lead candidate is a universal pneumococcal vaccine candidate given as a nasal spray now in preparation for clinical trials. Abera also explores applications in personalized immunotherapy.

Abera is taking Outer Membrane Vesicle technology to the next level by decorating them with high levels of pathogen specific antigens to efficient vaccine candidates.

Abera combines existing technologies, known antigens and break-through improvements with over 30 years of microbiological experience to create innovative vaccines.

pexels-edward-jenner-4033020

Abera is taking Outer Membrane Vesicle technology to the next level by decorating them with high levels of pathogen specific antigens to create efficient vaccine candidates.

Abera combines existing technologies, known antigens and break-through improvements with over 30 years of microbiological experiences into new, innovative vaccines.

hexa-03

NEWS

Abera is dedicated to the development of novel vaccines to save lives and increase health globally.

hexa-02 copy